KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry |
|
|
| Active, not recruiting | N/A | 4000 | US | Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox) | CareDx | Kidney Transplant Rejection | 06/25 | 12/25 | | |
| Active, not recruiting | 3 | 615 | Europe, Canada, US, RoW | Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo | CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | 09/25 | 08/27 | | |
